|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kojima T, Shah MA, Muro K, Francois E,
Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, Lee SH, et al:
Randomized phase III KEYNOTE-181 study of pembrolizumab versus
chemotherapy in advanced esophageal cancer. J Clin Oncol.
38:4138–4148. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cao Y, Qin S, Luo S, Li Z, Cheng Y, Fan Y,
Sun Y, Yin X, Yuan X, Li W, et al: Pembrolizumab versus
chemotherapy for patients with esophageal squamous cell carcinoma
enrolled in the randomized KEYNOTE-181 trial in Asia. ESMO Open.
7:1003412022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kato K, Cho BC, Takahashi M, Okada M, Lin
CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, et al:
Nivolumab versus chemotherapy in patients with advanced oesophageal
squamous cell carcinoma refractory or intolerant to previous
chemotherapy (ATTRACTION-3): A multicentre, randomised, open-label,
phase 3 trial. Lancet Oncol. 20:1506–1517. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang J, Xu J, Chen Y, Zhuang W, Zhang Y,
Chen Z, Chen J, Zhang H, Niu Z, Fan Q, et al: Camrelizumab versus
investigator's choice of chemotherapy as second-line therapy for
advanced or metastatic oesophageal squamous cell carcinoma
(ESCORT): A multicentre, randomised, open-label, phase 3 study.
Lancet Oncol. 21:832–842. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun JM, Shen L, Shah MA, Enzinger P,
Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, et al:
Pembrolizumab plus chemotherapy versus chemotherapy alone for
first-line treatment of advanced oesophageal cancer (KEYNOTE-590):
A randomised, placebo-controlled, phase 3 study. Lancet.
398:759–771. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L,
Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, et al: Nivolumab
combination therapy in advanced esophageal squamous-cell carcinoma.
N Engl J Med. 386:449–462. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q,
Zhang Y, Zhao K, Chen Z, Gao S, et al: Effect of camrelizumab vs
placebo added to chemotherapy on survival and progression-free
survival in patients with advanced or metastatic esophageal
squamous cell carcinoma: The ESCORT-1st randomized clinical trial.
JAMA. 326:916–925. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang
L, Wang B, Sun G, Ji Y, Cao G, et al: Sintilimab versus placebo in
combination with chemotherapy as first line treatment for locally
advanced or metastatic oesophageal squamous cell carcinoma
(ORIENT-15): Multicentre, randomised, double blind, phase 3 trial.
BMJ. 377:e0687142022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho
BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK,
Bondarenko I, et al: Pembrolizumab versus chemotherapy for
previously untreated, PD-L1-expressing, locally advanced or
metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised,
open-label, controlled, phase 3 trial. Lancet. 393:1819–1830. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
André T, Shiu KK, Kim TW, Jensen BV,
Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs
P, et al: Pembrolizumab in microsatellite-instability-high advanced
colorectal cancer. N Engl J Med. 383:2207–2218. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reck M, Schenker M, Lee KH, Provencio M,
Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney
K, et al: Nivolumab plus ipilimumab versus chemotherapy as
first-line treatment in advanced non-small-cell lung cancer with
high tumour mutational burden: Patient-reported outcomes results
from the randomised, open-label, phase III CheckMate 227 trial. Eur
J Cancer. 116:137–147. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mayne ST, Playdon MC and Rock CL: Diet,
nutrition, and cancer: Past, present and future. Nat Rev Clin
Oncol. 13:504–515. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Barreira JV: The role of nutrition in
cancer patients. Nutr Cancer. 73:2849–2850. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Buzby GP, Mullen JL, Matthews DC, Hobbs CL
and Rosato EF: Prognostic nutritional index in gastrointestinal
surgery. Am J Surg. 139:160–167. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakatani M, Migita K, Matsumoto S,
Wakatsuki K, Ito M, Nakade H, Kunishige T, Kitano M and Kanehiro H:
Prognostic significance of the prognostic nutritional index in
esophageal cancer patients undergoing neoadjuvant chemotherapy. Dis
Esophagus. 30:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bozkaya Y, Köstek O, Sakin A, Özyükseler
DT, Şakalar T and Çil İ: Is the prognostic nutritional index a
prognostic and predictive factor in metastatic non-small cell lung
cancer patients treated with first-line chemotherapy? Support Care
Cancer. 28:2273–2282. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mohri Y, Inoue Y, Tanaka K, Hiro J, Uchida
K and Kusunoki M: Prognostic nutritional index predicts
postoperative outcome in colorectal cancer. World J Surg.
37:2688–2692. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Azam F, Latif MF, Farooq A, Tirmazy SH,
AlShahrani S, Bashir S and Bukhari N: Performance status assessment
by using ECOG (Eastern Cooperative Oncology Group) score for cancer
patients by oncology healthcare professionals. Case Rep Oncol.
12:728–736. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rice TW, Gress DM, Patil DT, Hofstetter
WL, Kelsen DP and Blackstone EH: Cancer of the esophagus and
esophagogastric junction-Major changes in the American Joint
Committee on Cancer eighth edition cancer staging manual. CA Cancer
J Clin. 67:304–317. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chalian H, Töre HG, Horowitz JM, Salem R,
Miller FH and Yaghmai V: Radiologic assessment of response to
therapy: Comparison of RECIST Versions 1.1 and 1.0. Radiographics.
31:2093–2105. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brahmer JR, Abu-Sbeih H, Ascierto PA,
Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E,
Johnson DB, et al: Society for Immunotherapy of Cancer (SITC)
clinical practice guideline on immune checkpoint inhibitor-related
adverse events. J Immunother Cancer. 9:e0024352021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen C and Lu FC: The guidelines for
prevention and control of overweight and obesity in Chinese adults.
Biomed Environ Sci. 17 Suppl:1–36. 2004.PubMed/NCBI
|
|
25
|
Wei W, Zeng H, Zheng R, Zhang S, An L,
Chen R, Wang S, Sun K, Matsuda T, Bray F and He J: Cancer
registration in China and its role in cancer prevention and
control. Lancet Oncol. 21:e342–e349. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pan H, Cai S, Ji J, Jiang Z, Liang H, Lin
F and Liu X: The impact of nutritional status, nutritional risk,
and nutritional treatment on clinical outcome of 2248 hospitalized
cancer patients: A multi-center, prospective cohort study in
Chinese teaching hospitals. Nutr Cancer. 65:62–70. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rocha NP and Fortes RC: Total lymphocyte
count and serum albumin as predictors of nutritional risk in
surgical patients. Arq Bras Cir Dig. 28:193–196. 2015.(In English,
Portuguese). View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu J, Dai Y, Zhou F, Long Z, Li Y, Liu B,
Xie D, Tang J, Tan J, Yao K, et al: The prognostic role of
preoperative serum albumin/globulin ratio in patients with bladder
urothelial carcinoma undergoing radical cystectomy. Urol Oncol.
34:484 e481–484 e8. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Balkwill F: Tumour necrosis factor and
cancer. Nat Rev Cancer. 9:361–371. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brenner D, Blaser H and Mak TW: Regulation
of tumour necrosis factor signalling: Live or let die. Nat Rev
Immunol. 15:362–374. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Seaton K: Albumin concentration controls
cancer. J Natl Med Assoc. 93:490–493. 2001.PubMed/NCBI
|
|
32
|
Nassri A, Zhu H, Wang DH and Ramzan Z:
Serum albumin at diagnosis is an independent predictor of early
mortality in veteran patients with esophageal cancer. Nutr Cancer.
70:1246–1253. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qi Q, Song Q, Cheng Y and Wang N:
Prognostic significance of preoperative prognostic nutritional
index for overall survival and postoperative complications in
esophageal cancer patients. Cancer Manag Res. 13:8585–8597. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ray-Coquard I, Cropet C, Van Glabbeke M,
Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P,
Labidi I, et al: Lymphopenia as a prognostic factor for overall
survival in advanced carcinomas, sarcomas, and lymphomas. Cancer
Res. 69:5383–5391. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
De Giorgi U, Mego M, Scarpi E, Giuliano M,
Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN and
Cristofanilli M: Relationship between lymphocytopenia and
circulating tumor cells as prognostic factors for overall survival
in metastatic breast cancer. Clin Breast Cancer. 12:264–269. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Onodera T, Goseki N and Kosaki G:
Prognostic nutritional index in gastrointestinal surgery of
malnourished cancer patients. Nihon Geka Gakkai Zasshi.
85:1001–1005. 1984.(In Japanese). PubMed/NCBI
|
|
37
|
Liu N, Jiang A, Zheng X, Fu X, Zheng H,
Gao H, Wang J, Liang X, Tian T, Ruan Z and Yao Y: Prognostic
Nutritional Index identifies risk of early progression and survival
outcomes in advanced non-small cell lung cancer patients treated
with PD-1 inhibitors. J Cancer. 12:2960–2967. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hirahara N, Tajima Y, Fujii Y, Kaji S,
Yamamoto T, Hyakudomi R, Taniura T, Miyazaki Y, Kishi T and
Kawabata Y: Preoperative prognostic nutritional index predicts
long-term surgical outcomes in patients with esophageal squamous
cell carcinoma. World J Surg. 42:2199–2208. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gao X, Pan Y, Han W, Hu C, Wang C, Chen L,
Guo Y, Shi Y, Pan Y, Xie H, et al: Association of systemic
inflammation and body mass index with survival in patients with
resectable gastric or gastroesophageal junction adenocarcinomas.
Cancer Biol Med. 18:283–297. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gu WS, Fang WZ, Liu CY, Pan KY, Ding R, Li
XH and Duan CH: Prognostic significance of combined pretreatment
body mass index (BMI) and BMI loss in patients with esophageal
cancer. Cancer Manag Res. 11:3029–3041. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Potischman N, Hoover RN, Brinton LA,
Swanson CA, Herrero R, Tenorio F, de Britton RC, Gaitan E and
Reeves WC: The relations between cervical cancer and serological
markers of nutritional status. Nutr Cancer. 21:193–201. 1994.
View Article : Google Scholar : PubMed/NCBI
|
